Subscribe to Newsletter
Subspecialties Oncology, Genetics and epigenetics, Liquid biopsy, Technology and innovation

A Tumor-Agnostic Prognostic Tool?

Liquid biopsies are increasingly revolutionizing the way people with cancer are diagnosed, monitored, and treated. Clinical adoption of blood-based circulating tumor DNA (ctDNA) to track cancer progression is now widespread and many healthcare systems use ctDNA levels to help guide individualized therapy. In a new study, researchers investigated the prognostic value of elevated circulating tumor fraction (TF) calculated using ctDNA analysis.

The study used a multi-tumor cohort of patients from a nationwide clinicogenomic database. Each participant had one of four advanced cancer types: metastatic breast cancer, metastatic colorectal cancer, castration-resistant prostate cancer, or advanced non-small cell lung cancer. A total of 1,725 liquid biopsies were collected and TF levels were analyzed based on single-nucleotide polymorphism aneuploidy across the genome.

TF levels of at least 10 percent were closely associated with lower overall survival in univariate analyses across all cancer types; the biomarker’s prognostic impact is independent of most clinical features on multivariate analysis. However, certain clinical features formed an exception to this rule; the authors found that brain metastases, for instance, increased patient morbidity, but did not increase TF levels because these tumors may not shed ctDNA. . Exploratory analysis further found that TF is a successful prognostic biomarker across a range of different cutpoints, although more research on relevant cutpoints within each cancer type is still needed.

The researchers concluded that ctDNA TF can act as a biomarker for prognosis across multiple common cancer types in a real-world dataset. In the future, they hope that liquid biopsy for ctDNA TF testing will be incorporated into point-of-care settings to provide cancer therapy based on patient-level tumor biology.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. ZR Reichert et al., Ann Oncol, 34, 111 (2023). PMID: 36208697.
About the Author
Georgia Hulme

Associate Editor for the Pathologist

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register